Bicycle Therapeutics PLC
NASDAQ:BCYC

Watchlist Manager
Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC
NASDAQ:BCYC
Watchlist
Price: 14.73 USD 0.34%
Market Cap: 1B USD
Have any thoughts about
Bicycle Therapeutics PLC?
Write Note

Bicycle Therapeutics PLC
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bicycle Therapeutics PLC
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Bicycle Therapeutics PLC
NASDAQ:BCYC
Pre-Tax Income
-$169.6m
CAGR 3-Years
-36%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Pre-Tax Income
-$176.1m
CAGR 3-Years
-155%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Pre-Tax Income
-ÂŁ162.1m
CAGR 3-Years
-73%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Pre-Tax Income
-$208.4m
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Pre-Tax Income
-ÂŁ60.9m
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Pre-Tax Income
ÂŁ5.5m
CAGR 3-Years
-54%
CAGR 5-Years
-11%
CAGR 10-Years
-18%
No Stocks Found

Bicycle Therapeutics PLC
Glance View

Market Cap
1B USD
Industry
Biotechnology

Bicycle Therapeutics PLC, a pioneering force in biotechnology, was founded on a unique vision to transform medicine using a novel class of therapeutics known as Bicycles®. These are synthetic short peptides that combine the pharmacological capabilities of biologics with the manufacturing and distribution advantages of small molecules. The company's scientific ingenuity, originating from Cambridge, UK, has enabled it to engineer and develop a pipeline of drugs targeting areas with significant unmet medical needs, primarily in oncology and other severe diseases. Bicycle leverages its distinctive platform technology to design therapeutic candidates that offer high specificity and affinity, focusing on targets that have traditionally been challenging for conventional biologics and small molecules. Monetizing this innovative biotechnology hinges on Bicycle's strategic partnerships and collaborations with major pharmaceutical firms. These alliances allow the company to amplify its reach while sharing the risks and costs associated with drug development. By licensing their Bicycle® technology and therapeutic candidates to larger entities, Bicycle benefits from milestone payments and royalty streams, creating a sustainable revenue model. The company's revenue stream is thus a blend of upfront payments for access to their platform technology and the potential downstream success of these partners in developing and commercializing new therapeutic agents. Their unique approach and strong collaboration network position Bicycle Therapeutics at the forefront of next-generation drug discovery, striving to reshape treatment paradigms across multiple therapeutic areas.

BCYC Intrinsic Value
9.02 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Bicycle Therapeutics PLC's Pre-Tax Income?
Pre-Tax Income
-169.6m USD

Based on the financial report for Sep 30, 2024, Bicycle Therapeutics PLC's Pre-Tax Income amounts to -169.6m USD.

What is Bicycle Therapeutics PLC's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-38%

Over the last year, the Pre-Tax Income growth was -5%. The average annual Pre-Tax Income growth rates for Bicycle Therapeutics PLC have been -36% over the past three years , -38% over the past five years .

Back to Top